nach oben

Clinical Pharmacokinetics

Erschienen in:

01.09.2006 | Review Article

Pharmacokinetic and Pharmacodynamic Characteristics of Medications Used for Moderate Sedation

verfasst von: Dr Tong J. Gan

Erschienen in: Clinical Pharmacokinetics | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

The ability to deliver safe and effective moderate sedation is crucial to the ability to perform invasive procedures. Sedative drugs should have a quick onset of action, provide rapid and clear-headed recovery, and be easy to administer and monitor. A number of drugs have been demonstrated to provide effective sedation for outpatient procedures but since each agent has its own limitations, a thorough knowledge of the available drugs is required to choose the appropriate drug, dose and/or combination regimen for individual patients. Midazolam, propofol, ketamine and sevoflurane are the most frequently used agents, and all have a quick onset of action and rapid recovery. The primary drawback of midazolam is the potential for accumulation of the drug, which can result in prolonged sedation and a hangover effect. The anaesthetics propofol and sevoflurane have recently been used for sedation in procedures of short duration. Although effective, these agents require monitored anaesthesia care. Ketamine is an effective agent, particularly in children, but there is concern regarding emergence reactions. AQUAVAN® injection (fospropofol disodium), a phosphorylated prodrug of propofol, is an investigational agent possessing a unique and distinct pharmacokinetic and pharmacodynamic profile. Compared with propofol emulsion, AQUAVAN® is associated with a slightly longer time to peak effect and a more prolonged pharmacodynamic effect. Advances in the delivery of sedation, including the development of new sedative agents, have the potential to further improve the provision of moderate sedation for a variety of invasive procedures.

The use of trade names is for product identification purposes only and does not imply endorsement.

Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. Emerg Med Clin North Am 2005; 23: 503–17PubMedCrossRef

Javorski JJ, Hansen DD, Laussen PC, et al. Paediatric cardiac catheterization: innovations. Can J Anaesth 1995; 42: 310–29PubMedCrossRef

Cillo Jr JE. Propofol anesthesia for outpatient oral and maxillofacial surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 530–8PubMedCrossRef

Heuss LT, Froehlich F, Beglinger C. Changing patterns of sedation and monitoring practice during endoscopy: results of a nationwide survey in Switzerland. Endoscopy 2005; 37: 161–6PubMedCrossRef

Froehlich F, Schwizer W, Thorens J, et al. Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters. Gastroenterology 1995; 108: 697–704PubMedCrossRef

Cohen LB, Hightower CD, Wood DA, et al. Moderate level sedation during endoscopy: a prospective study using low-dose propofol, meperidine/fentanyl, and midazolam. Gastrointest Endosc 2004; 59: 795–803PubMedCrossRef

Kulling D, Bauerfeind P, Fried M, et al. Patient-controlled analgesia and sedation in gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 2004; 14: 353–68PubMedCrossRef

Heuss LT, Drewe J, Schnieper P, et al. Patient-controlled versus nurse-administered sedation with propofol during colonoscopy: a prospective randomized trial. Am J Gastroenterol 2004; 99: 511–8PubMedCrossRef

Bright E, Roseveare C, Dalgleish D, et al. Patient-controlled sedation for colonoscopy: a randomized trial comparing patient-controlled administration of propofol and alfentanil with physician-administered midazolam and pethidine. Endoscopy 2003; 35: 683–7PubMedCrossRef

10.

Lee DW, Chan AC, Sze TS, et al. Patient-controlled sedation versus intravenous sedation for colonoscopy in elderly patients: a prospective randomized controlled trial. Gastrointest Endosc 2002; 56: 629–32PubMedCrossRef

11.

Irwin MG, Thompson N, Kenny GN. Patient-maintained propofol sedation. Assessment of a target-controlled infusion system. Anaesthesia 1997; 52: 525–30PubMedCrossRef

12.

American Society of Anesthesiologists. Practice guidelines for sedation and analgesia by non anesthesiologists. Anesthesiology 2005; 96: 1004–17

13.

Gilger MA, Spearman RS, Dietrich CL, et al. Safety and effectiveness of ketamine as a sedative agent for pediatric GI endoscopy. Gastrointest Endosc 2004; 59: 659–63PubMedCrossRef

14.

Ristikankare M, Julkunen R, Mattila M, et al. Conscious sedation and cardiorespiratory safety during colonoscopy. Gastrointest Endosc 2000; 52: 48–54PubMedCrossRef

15.

Stewart RD. Nitrous oxide sedation/analgesia in emergency medicine. Ann Emerg Med 1985; 14: 139–48PubMedCrossRef

16.

Skues MA, Prys-Roberts C. The pharmacology of propofol. J Clin Anesth 1989; 1: 387–400PubMedCrossRef

17.

Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest Endosc Clin N Am 2004; 14: 247–68PubMedCrossRef

18.

Karan SB, Bailey PL. Update and review of moderate and deep sedation. Gastrointest Endosc Clin N Am 2004; 14: 289–312PubMedCrossRef

19.

Gepts E. Pharmacokinetic concepts for TCI anaesthesia. Anaesthesia 1998; 53 Suppl. 1: 4–12PubMedCrossRef

20.

Rodrigo MR, Irwin MG, Tong CK, et al. A randomised crossover comparison of patient-controlled sedation and patient-maintained sedation using propofol. Anaesthesia 2003; 58: 333–8PubMedCrossRef

21.

Egan TD. Target-controlled drug delivery: progress toward an intravenous “vaporizer” and automated anesthetic administration. Anesthesiology 2003; 99: 1214–9PubMedCrossRef

22.

Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999; 36: 13–26PubMedCrossRef

23.

Fragen RJ. Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Clin Ther 1997; 19: 405–19PubMedCrossRef

24.

Kanto J, Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet 1989; 17: 308–26PubMedCrossRef

25.

Persson J, Hasselstrom J, Maurset A, et al. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57: 869–75PubMedCrossRef

26.

Fechner J, Ihmsen H, Hatterscheid D, et al. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004; 101: 626–39PubMedCrossRef

27.

Fechner J, Ihmsen H, Schiessl C, et al. Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. Anesth Analg 2005; 100: 701–6PubMedCrossRef

28.

Pruitt RE, Cohen LB, Gibiansky E, et al. A randomized, open-label, multicenter, dose-ranging study of sedation with AQUAVAN® injection (GPI 15715) during colonoscopy. In: Digestive Disease Week; 2005 May 14–19, Chicago (IL), 2005

29.

Greenblatt DJ, Ehrenberg BL, Culm KE, et al. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. J Clin Pharmacol 2004; 44: 605–11PubMedCrossRef

30.

Wehrmann T, Kokabpick S, Lembcke B, et al. Efficacy and safety of intravenous propofol sedation during routine ERCP: a prospective, controlled study. Gastrointest Endosc 1999; 49: 677–83PubMedCrossRef

31.

Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. Gastrointest Endosc 1999; 49: 684–9PubMedCrossRef

32.

Full prescribing information. Richmond (ON): Novex Pharma, 2000 [online]. Available from URL: http://www.apotexcorp.com/pdf/Midazolam%20Inj%20bio%20&%20PI.pdf [Accessed 2005 Jun 20]

33.

Wilson KE, Girdler NM, Welbury RR. Randomized, controlled, cross-over clinical trial comparing intravenous midazolam sedation with nitrous oxide sedation in children undergoing dental extractions. Br J Anaesth 2003; 91: 850–6PubMedCrossRef

34.

Geisslinger G, Hering W, Kamp HD, et al. Pharmacokinetics of ketamine enantiomers. Br J Anaesth 1995; 75: 506–7PubMedCrossRef

35.

Hijazi Y, Boulieu R. Protein binding of ketamine and its active metabolites to human serum. Eur J Clin Pharmacol 2002; 58: 37–40PubMedCrossRef

36.

Sipe BW, Rex DK, Latinovich D, et al. Propofol versus midazolam/meperidine for outpatient colonoscopy: administration by nurses supervised by endoscopists. Gastrointest Endosc 2002; 55: 815–25PubMedCrossRef

37.

Patel SS, Goa KL. Sevoflurane: a review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs 1996; 51: 658–700PubMedCrossRef

38.

MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27: 190–5PubMedCrossRef

39.

Cook LB, Lockwood GG, Moore CM, et al. True patient-controlled sedation. Anaesthesia 1993; 48: 1039–44PubMedCrossRef

40.

Maitre PO, Funk B, Crevoisier C, et al. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol 1989; 37: 161–6PubMedCrossRef

41.

Zomorodi K, Donner A, Somma J, et al. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. Anesthesiology 1998; 89: 1418–29PubMedCrossRef

42.

Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272–7PubMed

43.

Bell GD, Spickett GP, Reeve PA, et al. Intravenous midazolam for upper gastrointestinal endoscopy: a study of 800 consecutive cases relating dose to age and sex of patient. Br J Clin Pharmacol 1987; 23: 241–3PubMedCrossRef

44.

Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50: 636–57PubMedCrossRef

45.

Frenkel C, Schuttler J, Ihmsen H, et al. Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Intensive Care Med 1995; 21: 981–8PubMedCrossRef

46.

Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657–65PubMedCrossRef

47.

Peyton SH, Couch AT, Bost RO. Tissue distribution of ketamine: two case reports. J Anal Toxicol 1988; 12: 268–9PubMed

48.

Xie H, Wang X, Liu G, et al. Analgesic effects and pharmacokinetics of a low dose of ketamine preoperatively administered epidurally or intravenously. Clin J Pain 2003; 19: 317–22PubMedCrossRef

49.

Tsui BC, Wagner A, Finucane B. Regional anaesthesia in the elderly: a clinical guide. Drugs Aging 2004; 21: 895–910PubMedCrossRef

50.

Goa KL, Noble S, Spencer CM. Sevoflurane in paediatric anaesthesia: a review. Paediatr Drugs 1999; 1: 127–53PubMedCrossRef

51.

Fechner J, Ihmsen H, Hatterscheid D, et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003; 99: 303–13PubMedCrossRef

52.

Schywalsky M, Ihmsen H, Tzabazis A, et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003; 20: 182–90PubMedCrossRef

53.

Gibiansky E, Strays MM, Gibiansky L, et al. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics. Anesthesiology 2005; 103: 718–29PubMedCrossRef

54.

Oldenhof H, de Jong M, Steenhoek A, et al. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther 1988; 43: 263–9PubMedCrossRef

55.

Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630–9PubMedCrossRef

56.

Short TG, Young KK, Tan P, et al. Midazolam and flumazenil pharmacokinetics and pharmacodynamics following simultaneous administration to human volunteers. Acta Anaesthesiol Scand 1994; 38: 350–6PubMedCrossRef

57.

Tolia V, Brennan S, Aravind MK, et al. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr 1991; 119: 467–71PubMedCrossRef

58.

Volkow ND, Wang GJ, Hitzemann R, et al. Decreased cerebral response to inhibitory neurotransmission in alcoholics. Am J Psychiatry 1993; 150: 417–22PubMed

59.

Abi-Dargham A, Krystal JH, Anjilvel S, et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. Am J Psychiatry 1998; 155: 1550–5PubMed

60.

Lau CE, Wang Y, Ma F. Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam. Eur J Pharmacol 1998; 346: 131–44PubMedCrossRef

61.

Golparvar M, Saghaei M, Sajedi P, et al. Paradoxical reaction following intravenous midazolam premedication in pediatric patients: a randomized placebo controlled trial of ketamine for rapid tranquilization. Paediatr Anaesth 2004; 14: 924–30PubMedCrossRef

62.

Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila) 1997; 36: 681–4CrossRef

63.

Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145–7PubMedCrossRef

64.

The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group I. Reversal of central benzodiazepine effects by flumazenil after conscious sedation produced by intravenous diazepam. Clin Ther 1992; 14: 895–909

65.

Short TG, Galletly DC. Residual psychomotor effects following reversal of midazolam sedation with flumazenil. Anaesth Intensive Care 1989; 17: 290–7PubMed

66.

Doufas AG, Bakhshandeh M, Bjorksten AR, et al. Induction speed is not a determinant of propofol pharmacodynamics. Anesthesiology 2004; 101: 1112–21PubMedCrossRef

67.

Cheuk DK, Wong WH, Ma E, et al. Use of midazolam and ketamine as sedation for children undergoing minor operative procedures. Support Care Cancer 2005; 13: 1001–9PubMedCrossRef

68.

Ketamine 2005 [online]. Available from URL: http://www.metrohealthanesthesia.com/edu/ivanes/ketamine5.htm [Accessed 2005 Aug 29]

69.

Hartvig P, Larsson E, Joachimsson PO. Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. J Cardiothorac Vasc Anesth 1993; 7: 148–53PubMedCrossRef

70.

Ibrahim AE, Ghoneim MM, Kharasch ED, et al. Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam. Anesthesiology 2001; 94: 87–94PubMedCrossRef

71.

Ibrahim AE, Taraday JK, Kharasch ED. Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol. Anesthesiology 2001; 95: 1151–9PubMedCrossRef

72.

Levitt DG, Schnider TW. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol 2005; 5: 1–29CrossRef

73.

Strays MM, Vanluchene AL, Gibiansky E, et al. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 2): pharmacodynamics and safety. Anesthesiology 2005; 103: 730–43CrossRef

74.

Moerman AT, Strays MM, Vereecke HE, et al. Remifentanil used to supplement propofol does not improve quality of sedation during spontaneous respiration. J Clin Anesth 2004; 16: 237–43PubMedCrossRef

75.

Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesthesiol Belg 2001; 52: 445–51PubMed

76.

Kucukyavuz Z, Cambazoglu M. Effects of low-dose midazolam with propofol in patient-controlled sedation (PCS) for apicectomy. Br J Oral Maxillofac Surg 2004; 42: 215–20PubMedCrossRef

77.

Mason KP, Michna E, Di Nardo JA, et al. Evolution of a protocol for ketamine-induced sedation as an alternative to general anesthesia for interventional radiologic procedures in pediatric patients. Radiology 2002; 225: 457–65PubMedCrossRef

78.

Walder B, Tramer MR. Analgesia and sedation in critically ill patients. Swiss Med Wkly 2004; 134: 333–46PubMed

79.

Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drags 2000; 59: 263–8CrossRef

80.

Jalowiecki P, Rudner R, Gonciarz M, et al. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005; 103: 269–73PubMedCrossRef

81.

Motsch J, Schmidt H, Bach A, et al. Long-term sedation with propofol and green discolouration of the liver. Eur J Anaesthesiol 1994; 11: 499–502PubMed

82.

Koch ME, Gevirtz C. Propofol may be safely administered by trained nonanesthesiologists. Con: Propofol: far from harmless. Am J Gastroenterol 2004; 99: 1208–11PubMedCrossRef

83.

Godambe SA, Elliot V, Matheny D, et al. Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department. Pediatrics 2003; 112: 116–23PubMedCrossRef

84.

Sternlo JE, Sandin RH. Recurrent respiratory depression after total intravenous anaesthesia with propofol and alfentanil. Anaesthesia 1998; 53: 378–81PubMedCrossRef

85.

Grauers A, Liljeroth E, Akeson J. Propofol infusion rate does not affect local pain on injection. Acta Anaesthesiol Scand 2002; 46: 361–3PubMedCrossRef

86.

Bryson HM, Fulton BR, Faulds D. Propofol: an update of its use in anaesthesia and conscious sedation. Drugs 1995; 50: 513–59PubMedCrossRef

87.

Nakane M, Iwama H. A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth 1999; 83: 397–404PubMedCrossRef

88.

Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia 1988; 43: 492–4PubMedCrossRef

89.

Chen SC, Rex DK. Review article: registered nurse-administered propofol sedation for endoscopy. Aliment Pharmacol Ther 2004; 19: 147–55PubMedCrossRef

90.

Ulmer BJ, Hansen JJ, Overley CA, et al. Propofol versus midazolam/fentanyl for outpatient colonoscopy: administration by nurses supervised by endoscopists. Clin Gastroenterol Hepatol 2003; 1: 425–32PubMedCrossRef

91.

Seifert H, Schmitt TH, Gultekin T, et al. Sedation with propofol plus midazolam versus propofol alone for interventional endoscopic procedures: a prospective, randomized study. Aliment Pharmacol Ther 2000; 14: 1207–14PubMedCrossRef

92.

Koshy G, Nair S, Norkus EP, et al. Propofol versus midazolam and meperidine for conscious sedation in GI endoscopy. Am J Gastroenterol 2000; 95: 1476–9PubMedCrossRef

93.

Knibbe CA, Zuideveld KP, De Jongh J, et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther 2002; 72: 670–84PubMedCrossRef

94.

Heuss LT, Schnieper P, Drewe J, et al. Safety of propofol for conscious sedation during endoscopic procedures in high-risk patients: a prospective, controlled study. Am J Gastroenterol 2003; 98: 1751–7PubMed

95.

Weston BR, Chadalawada V, Chalasani N, et al. Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol 2003; 98: 2440–7PubMedCrossRef

96.

Badrinath S, Avramov MN, Shadrick M, et al. The use of a ketamine-propofol combination during monitored anesthesia care. Anesth Analg 2000; 90: 858–62PubMedCrossRef

97.

Eilers H, Niemann C. Clinically important drag interactions with intravenous anaesthetics in older patients. Drags Aging 2003; 20: 969–80CrossRef

98.

Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57PubMedCrossRef

99.

Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drag interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999; 39: 1109–25PubMed

100.

Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14–24PubMedCrossRef

101.

Ibrahim A, Park S, Feldman J, et al. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 2002; 96: 88–95PubMedCrossRef

102.

Vuyk J. Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. J Clin Anesth 1997; 9: 23S–6SPubMedCrossRef

103.

Vargo JJ. Propofol may be safely administered by trained nonanesthesiologists. Pro: Propofol demystified: it is time to change the sedation paradigm. Am J Gastroenterol 2004; 99: 1207–8PubMedCrossRef

Titel: Pharmacokinetic and Pharmacodynamic Characteristics of Medications Used for Moderate Sedation
verfasst von: Dr Tong J. Gan
Publikationsdatum: 01.09.2006
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 9/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645090-00001

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pharmacokinetic and Pharmacodynamic Characteristics of Medications Used for Moderate Sedation

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2006

Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients

Lack of Effect of Sex and Disease State on the Pharmacokinetics of Porfimer Sodium

Pharmacokinetic Considerations in the Treatment of CNS Tumours

Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children